Aravive Higher on Progress in Phase 1b Trial of Kidney-Cancer Drug thestreet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thestreet.com Daily Mail and Mail on Sunday newspapers.
Author Bio
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.
Follow @keithspeights
Several biotech stocks were big winners last year, with the race to develop COVID-19 vaccines in full swing. German biotech
BioNTech (NASDAQ:BNTX) was one of them. But can the company deliver another strong performance this year? In this
Motley Fool Live video recorded on Jan. 13, 2021, Healthcare and Cannabis Bureau Chief Corinne Cardina and Fool.com writer Keith Speights discuss what 2021 might have in store for BioNTech.
Author Bio
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.
Follow @keithspeights
Some investors think the ship has already sailed when it comes to investing in
Moderna (NASDAQ:MRNA). With a market cap of well over $50 billion, Moderna s opportunities for its COVID-19 vaccine mRNA-1273 seem to largely be baked into its share price.
I d definitely agree that Moderna s valuation a couple of months ago was much more attractive than it is now. However, I don t think it s necessarily too late to buy the biotech stock. Here are three reasons why.